| PCS | palliative care service; Patient Care System; patterns of care study; pelvic congestion syndrome; ph... |
|---|---|
| SSI | segmental sequential irradiation; shoulder subluxation inhibition; small-scale integration; Social S... |
| SSR | site-specific recombination; somatosensory response; surgical supply room |
| STS | sequence tagged site; serologic test for syphilis; sodium tetradecyl sulfate; sodium thiosulfate; st... |
| UAS | upper abdomen surgery; upstream activation site |
| deoxyribonucleases, type III site-specific | <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity. The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers. Registry number: EC 3.1.21.5 (12 Dec 1998) |
|---|---|
| deoxyribonucleases, type II site-specific | <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers. Registry number: EC 3.1.21.4 (12 Dec 1998) |
| deoxyribonucleases, type I site-specific | <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers. Registry number: EC 3.1.21.3 (12 Dec 1998) |
| DNA-(apurinic or apyrimidinic site) lyase | <enzyme> Formerly EC 3.1.25.2 Registry number: EC 4.2.99.18 Synonym: endodeoxyribonuclease (apurinic or apyrimidinic), apurinic endonuclease, apurinic DNA endonuclease, purine insertase, endonuclease iv, DNA repair endonuclease, endonuclease vi, endonuclease iv, E coli, bap1, bovine ap endonuclease I, nfo gene product, apci, apcii, apciii, ap lyase, ap endonuclease, hap1 DNA repair enzyme, apurine-apyrimidine endonuclease (26 Jun 1999) |
| DNAse i hypersensitivity site | <molecular biology> A site on a DNA molecule that is especially prone to being cut apart by the endonuclease enzyme DNase I, which breaks down DNA into smaller fragments by cleaving phosphodiester bonds. These sites tend to be near active genes, which are regularly transcribed. (09 Oct 1997) |
| trophoblastic tumour, placental site | A tumour that arises from the trophoblast of the placental bed and is composed mainly of cytotrophoblastic cells. It encompasses lesions of low- and high-grade malignancy. (holland et al., cancer medicine, 3d ed, p1691) (12 Dec 1998) |
| expression site | The location in the genome of the gene for the variable surface glycoprotein that is currently being expressed (an expression-linked copy) by the trypanosome (a parasitic protozoan which causes the disease African sleeping sickness). most of these sites are near the ends, or telomeres, of a chromosome. (09 Oct 1997) |
| upstream activation site | A DNA sequence that regulates transcription like an enhancer but does notwork if its located downstream from a promoter. (09 Oct 1997) |
| fragile site | Places on chromosomes that tend to break more often than other places. These places also tend to be where chromosomal translocations (a type of chromosomal mutation) occur. (09 Oct 1997) |
| ligand binding site | The site on a protein's surface that binds a ligand; equivalent to the active site if the ligand is the substrate of an enzyme. (05 Mar 2000) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |